Bioactive properties and clinical safety of a novel milk protein peptide

  • Richard B Kreider1Email author,

    Affiliated with

    • Mike Iosia2,

      Affiliated with

      • Matt Cooke3,

        Affiliated with

        • Geoffrey Hudson4,

          Affiliated with

          • Chris Rasmussen1,

            Affiliated with

            • Helen Chen5,

              Affiliated with

              • Olof Mollstedt5 and

                Affiliated with

                • Men-Hwei Tsai5

                  Affiliated with

                  Nutrition Journal201110:99

                  DOI: 10.1186/1475-2891-10-99

                  Received: 11 August 2011

                  Accepted: 26 September 2011

                  Published: 26 September 2011



                  Milk protein fractions and peptides have been shown to have bioactive properties. This preliminary study examined the potential mechanisms of action and clinical safety of novel milk protein peptide (MP).


                  A novel MP mixture inhibits the tyrosine kinase activity of epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor 2 (VEGFR2), and insulin receptor (IR) with IC50 of 9.85 μM, 7.7 μM, and 6.18 μM respectively. In vitro, this multi-kinase inhibitor causes apoptosis in HT-29 colon cancer cells, and in a C. elegans worm study, showed a weak but significant increase in lifespan. A six week double-blind, placebo-controlled study involving 73 healthy volunteers demonstrated that the MP mixture is safe to consume orally. All clinical blood markers remained within normal levels and no clinically significant side effects were reported. There was some evidence of improved insulin sensitivity, neutrophil-to-lymphocyte ratio (NLR), and quality of life assessment of role of physical function.


                  These data in combination with the observed in vitro anti-cancer properties warrant further clinical studies to investigate this MP mixture as a potential clinical nutrition intervention for improving the quality of life and clinical outcomes in cancer patients.

                  Trial Registration



                  Health Cancer Neutrophil Lymphocyte Ratio Insulin Sensitivity Quality of Life


                  Clinical nutrition products are specifically formulated nutrients to help people manage various health conditions. With recent advances in biotechnology, new techniques and tools are now available to isolate components from food that have additional health enhancing properties. Peptides are good candidates for advanced clinical nutrition and supplements since they are easily absorbed, and unlike many plant based compounds, peptides are amino acids that can be eliminated naturally by the body with less potential toxicity [1]. We have isolated a peptide mixture from regular cow's milk that preliminary basic and clinical research indicates may have some beneficial bioactive properties. The purpose of this study was to: (1) characterize the molecular mechanism of action; (2) assess the mixture's safety in healthy human subjects; and, (3) look for trends in potential improvements that can be further explored in future clinical trials in cancer patients.


                  Milk peptides

                  A milk peptide product AminoAct® (MP) was prepared from normal cow's milk and supplied by OncoNutrition (Riverside, CA). A whey based peptide fraction was isolated from pasteurized skim milk using proprietary enzyme digestion and buffers. The final product was supplied in an aqueous solution. Table 1 presents the nutrient panel of the MP product examined in this report.
                  Table 1

                  Nutrient content of milk peptide product (per 100 ml).



                  Calories (kcal)


                  Fat (kcal)


                  Fat (g)


                  Saturated Fat (g)


                  Sodium (mg)


                  Protein (g)


                  Calcium (mg)


                  Trans Fat (g)


                  Cholesterol (mg)


                  Sugars (g)


                  Carbohydrate (g)


                  Dietary Fiber (g)


                  Iron (mg)




                  Basic Research Trials

                  Kinase IC50 Profiling

                  The inhibitory effects of the milk peptide mixture on epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor 2 (VEGFR2), and insulin receptor (IR) kinases were performed at Reaction Biology Corporation (Malvern, PA). Briefly, specific kinase/substrate pairs along with required cofactors were prepared in reaction buffer; 20 mM Hepes pH 7.5, 10 mM MgCl2, 1 mM EGTA (ethylene glycol tetraacetic acid), 0.02% Brij35, 0.02 mg/ml BSA (bovine serum albumin), 0.1 mM Na3VO4, 2 mM DTT (dithiothreitol), 1% DMSO (dimethyl sulfoxide). Compounds were delivered into the reaction, followed 20 minutes later by addition of a mixture of ATP (Sigma, St. Louis MO) and 33P ATP (Perkin Elmer, Waltham MA) to a final concentration of 10 μM. Reactions were carried out at room temperature for 120 min, followed by spotting of the reactions onto P81 ion exchange filter paper (Whatman Inc., Piscataway, NJ). Unbound phosphate was removed by extensive washing of filters in 0.75% Phosphoric acid. After subtraction of background derived from control reactions containing inactive enzyme, kinase activity data was expressed as the percent of remaining kinase activity in test samples compared to vehicle (dimethyl sulfoxide) reactions. Ten concentrations of milk peptides, with highest at 500 μM concentration, were tested. IC50 values and curve fits were obtained using Prism (GraphPad Software, La Jolla, California).

                  HT-29 Colon Cancer Cell Apoptosis Assay

                  HT-29 human colon cancer cells were grown in a 72-well Terasaki plate until 80% confluent in McCoy's 5A medium, 10% FBS [2]. Vehicle, commercial hydrolyzed whey protein (Thorne Research, Sandpoint, ID), and MP mixture were added separately to each well in triplicates for a final concentration of 0.68 μg/μl media. Pictures were taken after 20 hr incubation.

                  C.elegans Lifespan Assay

                  The effects of the MP mixture on the lifespan of C. elegans were performed at the University of Utah C. elegans Research Core Facility (Salt Lake City, Utah) using previously published methods [3]. Nematode Growth Media (NGM) agar plates were prepared containing either no peptides, or 20 μg/ml, 6.66 μg/ml, 0.66 μg/ml concentrations of the MP mixture. All plates were seeded with E. Coli strain OP50. Experimental plates were prepared in triplicate. Approximately 10 N2 (wild type strain) worms were cultured on four standard agar plates or plates containing different dosages of MP. In addition to using N2 worms on standard plates as controls, other control plates included 40L4 mutant daf-2 (el370) and 40 L4 daf-16(m26) larvae. The mean number of surviving worms for each day was recorded, and the number of animals died on each day was calculated and the values were used in log rank tests to examine statistically significant differences. The results were simultaneously evaluated using the χ2 test and values above 1.0 at a p-value of > 0.01 are considered statistically different when comparing longevity of N2 worms on standard plates versus the test sample.

                  Clinical Safety Study


                  The clinical trial was conducted as a placebo-controlled, double-blind, parallel arm repeated measures study conducted in a university setting. The protocol was reviewed and approved by a human participants internal review board (IRB) and written informed consent was obtained from all patients prior to the initiation of study. Subjects who were apparently healthy between the ages of 35 - 60 years who had body mass index (BMI) ranging between 27 and 40 with no known metabolic disorders, history of milk allergies, and/or medical conditions were eligible to participate in the study. Subjects were matched according to gender, age, and body mass and randomized to consume a placebo or the MP mixture in a free living condition. Table 2 presents participant demographics based on gender and group randomization. Eighty-one subjects volunteered to participate in this study with 73 completing the study. Two males and six females did not complete the study. Three cited time constraints with their schedules, two missed multiple testing sessions, 2 did not give a specific explanation and one participant who was in the supplement group withdrew due to gastrointestinal distress which could have been instigated by ingestion of the milk or supplement.
                  Table 2

                  Participant descriptive data.





                  Group × Gender


                  Age (yr)


                  47.0 ± 8

                  45.8 ± 8




                  45.2 ± 10

                  50.6 ± 8


                  Height (cm)


                  177 ± 11

                  163 ± 7




                  176 ± 6

                  163 ± 8


                  Weight (kg)


                  99.1 ± 13

                  82.5 ± 10




                  98.9 ± 13

                  83.8 ± 14


                  BMI (kg/m2)


                  31.7 ± 4

                  30.8 ± 3




                  31.8 ± 4

                  31.5 ± 4


                  Body Fat (%)


                  31.1 ± 7

                  40.0 ± 5




                  30.8 ± 4

                  43.6 ± 4


                  Data are means and ± standard deviations. MP = Milk Protein. P = Placebo.

                  Supplementation protocol

                  The MP mixture or a flavored water and glycerol placebo were administered in three escalating dosages based on body weight over a six week period according to the supplementation schedule described in Table 3. Subjects took 1/2 dosage, mixed with 1/2 cup milk immediately after breakfast and consumed the remaining 1/2 dosage with 1/2 cup milk immediately after dinner. Supplementation compliance was monitored by having participants return empty bottles of the supplements as well as submitting a supplement log documenting when supplements were ingested.
                  Table 3

                  Supplementation dosing schedule (ml/d).

                  Weight Range

                  Dosage for Week 1 & 2

                  Dosage for Week 3 & 4

                  Dosage for Week 5 & 6

                  < 100 kg




                  101 - 109 kg




                  > 110 kg




                  Clinical assessments

                  Subjects were evaluated at baseline, 3 weeks, and 6 weeks for general health markers. The independent variable was MP supplementation. Dependent variables included energy intake; body composition; resting heart rate and blood pressure; a complete whole blood and serum clinical chemistry panel; serum insulin and leptin; measures of quality of life; and, symptoms and side effects surveys.


                  Participants recorded all food and fluid intake for four days prior to each testing session which included three weekdays and one weekend day. Dietary inventories were reviewed by a registered dietitian and analyzed using the ESHA Food Processor (Version 8.6) Nutritional Analysis software (ESHA Research Inc., Salem, OR). Height and body mass were determined using a calibrated electronic scale (Cardinal Detecto Scale Model 8430, Webb City, Missouri). Body composition (excluding cranium) was assessed using a Hologic Discovery W (Hologic Inc., Waltham, MA) dual energy x-ray absorptiometer (DXA) equipped with APEX Software (APEX Corporation Software, Pittsburg, PA). Resting heart rate was determined by palpitation of the radial artery and blood pressure was assessed by auscultation of the brachial artery using a mercurial sphygmomanometer using standard clinical procedures [4].

                  Whole blood samples were analyzed for complete blood counts with platelet differentials using an Abbott Cell Dyn 3500 (Abbott Laboratories, Abbott Park, IL) automated hematology analyzer. Serum samples were analyzed for a complete metabolic panel using a Dade Behring Dimension RXL (Siemans AG, Munich, Germany) automated clinical chemistry analyzer. Coefficient of variation (range: 1.0 to 9.6%) for tests performed was similar to previously published data for these tests [5]. Serum insulin and leptin were determined using commercially available immuno-absorbent assay (ELISA) kits (Diagnostic Systems Laboratories, Webster, TX) using a Wallac Victor-1420 microplate reader (Perkin-Elmer Life Sciences, Boston, MA) according to kit specifications. Intra-assay and inter-assay coefficient of variation were 4%-7% for insulin and 2% - 8% for leptin. The homeostasis model assessment for estimating insulin resistance (HOMAIR) was calculated as the product of fasting glucose times fasting insulin expressed in conventional units divided by 405 [6]. Participants also completed the SF-36 Quality of Life (QOL) inventory which has been used to assess physical and mental components related to QOL [7] as well as a symptom and side effect questionnaire.

                  Statistical analysis

                  Related variables were grouped together and analyzed by multivariate analysis of variance (MANOVA) with repeated measures using PASW Statistics 18.0.2 software (SPSS, Chicago, IL). Non-correlated variables were analyzed by univariate repeated measures analysis of variance (ANOVA). Delta values were calculated and analyzed on select variables by MANOVA for repeated measures to assess changes from baseline values. Data were considered statistically significant when the probability of type I error was 0.05 or less. If a significant group, treatment and/or interaction alpha was observed, Tukey's honestly significant differences post-hoc analyses were performed.


                  Basic Research Findings

                  A proprietary MP mixture was screened for tyrosine kinase inhibitory activity. Notably, this particular peptide mixture's IC50 for EGFR, VEGFR2, and IR are 9.85 μM, 7.7 μM, and 6.18 μM respectively (Figure 1). In vitro, the peptide mixture at 0.68 μg/μl causes cell death in HT-29 human colon cancer cell line; whereas commercial hydrolyzed whey powder did not cause cell death (Figure 2). Hoechst dye staining showed the cell death is accompanied with nuclear condensation and DNA fragmentation, suggesting an apoptotic cell death, and the apoptotic death is dose dependent (data not shown). In vivo, C.elegans worms were used to test the impact of MP on lifespan. Wild type L4 larval N2 worms were fed with or without the MP. In the group that was fed with agar containing 20 μg/ml peptides, the median survival where 50% worms were alive was Day 15, compared to Day 13. The last worm in the controlled group died at Day 20, in contrast to Day 25 in the experimental group fed with agar containing milk peptides (Figure 3). Statistical analysis of N2 standard vs.MP fed worms showed a value of 6.1 (p = 0.014) from χ2 test, indicating a weak but significant statistical significance. Lower concentrations of peptides did not yield significant lifespan expansion (data not shown).
                  Figure 1

                  Determination of tyrosine kinase inhibitory properties of novel milk peptide mixture MP. The novel milk peptide mixture was screened against a panel of kinases. Specifically, the IC50 for inhibition of epidermal growth factor receptor (EGFR), insulin receptor (IR), and vascular epidermal growth factor receptor-2 (VEGFR2) were determined using a 10-point dose response radiolabeled assay.

                  Figure 2

                  Comparison of HT-29 human colon cancer cell death between commercially available whey peptides and the MP mixture. HT-29 colon cancer cells were incubated with 0.68 μg/μl concentration of commercial hydrolyzed whey protein, MP peptides, and vehicle only (control). Pictures were taken after 20 hours of incubation.

                  Figure 3

                  MP fedC. elegansworms have a weak but significant increase in life-span. -- represents survival of wild-type (N2) animals fed with standard agar; --- represents survival of wild-type animals fed with agar containing 20 μg/ml peptides. Control: n = 40, m = 13; Milk peptides (MP): n = 40, m = 15 (P = 0.0136). n represents the number of animals observed in each experiment. m represents the median adult life span.

                  Clinical Safety Study Findings

                  No significant MANOVA or univariate ANOVA group × time effects were seen in energy intake, macronutrient intake, or body composition between groups. However, univariate ANOVA analysis revealed small albeit significant differences in changes in fat mass (P -0.23 ± 1.3; MP 0.44 ± 1.0 kg, p = 0.04) and body fat percentage (P -0.57 ± 1.6; MP 0.2 ± 1.0%, p = 0.03) over time between groups. Resting heart rate decreased to a greater degree in the P group (P -5.4 ± 7; MP -1 ± 7 beats/min, p = 0.01) with no differences observed between groups in resting systolic or diastolic blood pressure.

                  Whole blood analysis revealed no overall MANOVA group × time effects (p = 0.60) among white blood cells, neutrophils, lymphocytes, monocytes, eosinphils, basophils, red blood cells, hemoglobin, hematocrit, mean cell volume, or mean corpuscle hemoglobin count. A significant univariate ANOVA quadratic interaction affect (p = 0.05) was observed among groups in the neutrophil to lymphocyte ratio (Figure 4). Serum analysis revealed no overall MANOVA or univariate group × time effects among triglycerides, total cholesterol, high density lipoproteins, low density lipoproteins, or uric acid; creatine kinase, lactate dehydrogenase, aspartate amino transaminase, alanine amino transaminase, gamma glutamyl transaminase, or alkaline phosphatase; and, blood urea nitrogen (BUN), creatinine, BUN to creatinine ratio, calcium, total protein, albumin, or total bilirubin. Figure 5 presents changes in hormonal responses observed during the study. Although no statistically significant interactions were observed, some potentially interesting trends were observed which warrant further investigation.
                  Figure 4

                  Neutrophil to lymphocyte ratio values observed for the placebo (P) and milk protein (MP) groups over time.

                  Figure 5

                  Change in hormonal responses from baseline observed for the placebo (P) and milk protein (MP) groups. HOMAIR represents homeostatic model assessment of insulin resistance.

                  MANOVA analysis indicated that a group × time trend (p = 0.06) was observed between groups in QOL indices. As Figure 6 presents, univariate ANOVA analysis revealed that participants in the MP group observed a significantly greater increase (p = 0.01) in role physical (i.e., ability to work and perform daily activities). No significant side effects were observed for frequency of dizziness, racing heart rate, skip heart beats, shortness of breath, nervousness, or blurred vision. Moreover, no subject was medically removed from the study or was referred for medical consultation.
                  Figure 6

                  Comparison between placebo and MP group in role physical measure of quality of life.


                  Milk represents a unique source of nutrients and biologically active components that act in synergy, as well as independently. Emerging evidence indicates that the protein component of milk represents a variety of biologically active proteins/peptides that function as anti-hypertensive agents, antimicrobial factors, food intake modifiers and immune regulatory factors [8, 9]. Interestingly, many bioactive peptides are inactive within their parent milk proteins, and upon release during digestion or food processing, they may act as regulatory compounds with hormone-like activity [10, 11]. Additionally, there are increasing studies showing that bioactive milk peptides can be absorbed intact from the intestinal lumen into the blood circulation - these may thus serve as novel functional food ingredients or pharmaceutical agents [1215].

                  Using a proprietary enzyme digestion and buffer isolation method, we purified a group of peptides from the whey fraction of regular cow's milk and screened against a panel of kinases. In particular, this milk peptide mixture shows inhibitory effects against EGFR, VEGFR2, and IR. EGFR is often overexpressed in non-small cell lung cancer (NSCLC) and a variety of common solid tumors. EGFR signaling is generally associated with cancer invasion, metastasis, chemotherapy resistance, and poor prognosis [16, 17]. It has also been reported that inhibition of EGFR may lead to apoptosis in certain cancer cell lines [18]. Gefitinib (Iressa ® , AstraZeneca plc, London, UK) and Erlotinib (Tarceva ® , Genentech, Inc., San Francisco, CA) are examples of anti-cancer drugs targeting EGFR-TK. Interestingly, MP mixture is also able to cause significant cell death in HT29 colon cancer cells, whereas neither commercially available hydrolyzed whey proteins nor whole milk proteins exhibited the same property. This may be because most commercial hydrolyzed whey proteins contained too small amount of bioactive peptides or the process of spray drying deactivated the activity.

                  This novel MP mixture also inhibits insulin receptor signaling. Interestingly, mutations in daf-2, a gene that encodes an insulin-like receptor in C. elegans worm, have been shown to double the lifespan of the worms [19]. The gene is known to regulate reproductive development, ageing, resistance to oxidative stress, thermotolerance, resistance to hypoxia and also resistance to bacterial pathogens [20]. Therefore, we next tested this unique MP mixture effect on the lifespan of C. elegans worms. Statistical analysis of the result suggested that N2 worms fed with agar containing 20 μg/ml concentration of milk peptides increased the median lifespan by 15.4% (p = 0.014). Based on these data, we hypothesize that this milk peptide mixture may be a novel supplement ingredient for anti-aging and cancer preventive regimen.

                  Since MP has multi-kinase inhibitory activity in the micromolar range, we first conducted toxicology studies to measure the safety of these peptides. An acute and a 28-day sub-acute toxicology study showed no apparent adverse effects in rodents following oral administration of the peptides. Encouraged by the results, we conducted an 80 subject, double blind, placebo controlled study in healthy volunteers. The main purpose was to assess the safety of the milk peptides at three escalating dosages.

                  The clinical analyses showed that the MP mixture did not cause significant side effects in healthy human subjects. All blood and hormonal markers remained in normal ranges. There was a mean trend toward improving insulin sensitivity as assessed using HOMAIR that warrants additional study. This could potentially have beneficial effects for individuals with insulin resistance. However, these changes were not significant due to the large variability in responses observed. Additional study evaluating the effects of these milk peptides on glucose tolerance in individuals with and without insulin resistance would help elucidate this potential effect.

                  Another encouraging trend was the lowering of neutrophil to lymphocyte ratio (NLR). The neutrophil-lymphocyte ratio is a general marker of immunity and inflammatory status. Research has shown that elevated NLR to be a prognostic indicator of poor chemotherapy outcomes in advanced colorectal cancer and poor survival after colorectal liver metastases [2123]. The potential impact of MP supplementation on lowering NLR could be used as a clinical nutritional intervention for these categories of cancer patients. In addition, these peptides have been shown to have in vitro anti-EGFR and VEGFR2 activity. EGFR is commonly elevated in many advanced cancers, and VEGFR2 is considered one of the key regulators of tumor-induced angiogenesis [24, 25]. Together, this novel milk peptide mixture's anti-cancer and inflammatory reducing properties may be a safe, effective supplement to help cancer patients undergoing chemotherapy to obtain better clinical outcome.

                  In summary, preliminary experiments suggest that there may be some potentially beneficial applications of this novel MP mixture and that six weeks of human consumption appears to be safe. The limitation of this first clinical study is that the human subjects were healthy individuals. Additional clinical studies are currently underway to further elucidate the milk peptides' impact on the progression of cancer and quality of life in cancer patients.



                  We would like to thank the individuals who participated in this study as well as all of the students and administrative support staff's at Baylor University and Texas A&M University who assisted in conducting the clinical trial. We would also like to thank Dr. Ron Wilson for providing medical supervision.

                  Authors’ Affiliations

                  Exercise and Sport Nutrition Laboratory, Department of Health & Kinesiology, Texas A&M University
                  Department of Health, Exercise Science, and Secondary Education, Lee University
                  Schools of Biomedical & Health Sciences, Victoria University
                  School of Human Performance and Recreation, University of Southern Mississippi
                  Ambryx Biotechnology, Inc.


                  1. Nagpal R, Behare P, Rana R, Kumar A, Kumar M, Arora S, Morotta F, Jain S, Yadav H: Bioactive peptides derived from milk proteins and their health beneficial potentials: an update. Food Funct 2011, 2:18–27.View Article
                  2. Lien E, Jackson J, Kuhlman C, Pramuk K, Lonnerdal B, Janszen D: Variations in concentrations of lactoferrin in human milk: a nine country survey. Adv Exp Med Biol 2004, 554:423–426.
                  3. Domellof M, Hemell O, Dewey KG, Cohen RJ, Lonnerdal B: Factors influencing concentrations of iron, zinc, and copper in human milk. Adv Exp Med Biol 2004, 554:355–358.
                  4. Kaminsky LA, Bryant CX, Mahler DA, Durstine JL, Humphrey RH: ACSM's Guidelines for Exercise Testing and Prescription. 8th edition. Baltimore, MD: Lippincott, Williams & Wilkins; 2009.
                  5. Cuka S, Dvornik S, Drazenovic K, Mihic J: Evaluation of the Dade Behring Dimension RxL clinical chemistry analyzer. Clin Lab 2001, 47:35–40.
                  6. McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis-Barned NJ, Temple LA, Duncan AW: Diagnosing insulin resistance in the general population. Diabetes Care 2001, 24:460–464.View Article
                  7. Ware JE Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A: Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995, 33:AS264–279.View Article
                  8. Lonnerdal B: Nutritional and physiologic significance of human milk proteins. Am J Clin Nutr 2003, 77:1537S-1543S.
                  9. Lonnerdal B: Human milk proteins: key components for the biological activity of human milk. Adv Exp Med Biol 2004, 554:11–25.
                  10. Jain A, Lense S, Linehan JC, Raugei S, Cho H, DuBois DL, Shaw WJ: Incorporating peptides in the outer-coordination sphere of bioinspired electrocatalysts for hydrogen production. Inorg Chem 2011, 50:4073–4085.View Article
                  11. Korhonen H, Pihlanto A: Food-derived bioactive peptides--opportunities for designing future foods. Curr Pharm Des 2003, 9:1297–1308.View Article
                  12. Vermeirssen V, Van Camp J, Verstraete W: Bioavailability of angiotensin I converting enzyme inhibitory peptides. Br J Nutr 2004, 92:357–366.View Article
                  13. Phelan M, Kerins D: The potential role of milk-derived peptides in cardiovascular disease. Food Funct 2011, 2:153–167.View Article
                  14. Drouet L, Bal Dit Sollier C, Mazoyer E, Levy-Toledano S, Jolles P, Fiat A: Use of k- caseinoglycopeptide for preparation of composition, especially a drug, for prevention and treatment of thrombosis. 1990.
                  15. Drouet L, Bal Dit Sollier C, Mazoyer E, Levy-Toledano S, Jolles P, Fiat A: Method of preventing or treating thrombosis using kappa-caseinoglycopeptide as active ingredient. 1990.
                  16. Khazaie K, Schirrmacher V, Lichtner RB: EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 1993, 12:255–274.View Article
                  17. Lurje G, Lenz HJ: EGFR signaling and drug discovery. Oncology 2009, 77:400–410.View Article
                  18. Okamoto K, Okamoto I, Okamoto W, Tanaka K, Takezawa K, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K: Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations. Cancer Res 2010, 70:10402–10410.View Article
                  19. Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R: A C. elegans mutant that lives twice as long as wild type. Nature 1993, 366:461–464.View Article
                  20. Baumeister R, Schaffitzel E, Hertweck M: Endocrine signaling in Caenorhabditis elegans controls stress response and longevity. J Endocrinol 2006, 190:191–202.View Article
                  21. Chua W, Charles KA, Baracos VE, Clarke SJ: Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011, 104:1288–1295.View Article
                  22. Ding PR, An X, Zhang RX, Fang YJ, Li LR, Chen G, Wu XJ, Lu ZH, Lin JZ, Kong LH, et al.: Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis 2010, 25:1427–1433.View Article
                  23. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ: Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005, 91:181–184.View Article
                  24. Brekken RA, Thorpe PE: Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res 2001, 21:4221–4229.
                  25. Shibuya M: Vascular endothelial growth factor (VEGF)-Receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium 2006, 13:63–69.View Article


                  © Kreider et al; licensee BioMed Central Ltd. 2011

                  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.